TNF antagonists for ankylosing spondylitis

Drug and Therapeutics Bulletin

Volumn 43, Issue 3, 2005, Pages 19-22

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; INFLIXIMAB; LYMPHOTOXIN; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANALGESIA; ANAPHYLACTIC SHOCK; ANKYLOSING SPONDYLITIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSENSUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BINDING; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPNEA; EDEMA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; GOLD THERAPY; HEADACHE; HUMAN; INJECTION PAIN; INJECTION SITE REACTION; JOINT STIFFNESS; LUPUS ERYTHEMATOSUS; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; PRURITUS; QUESTIONNAIRE; SACROILIAC JOINT; SEPSIS; SKIN BRUISING; SPINAL PAIN; SPINE MOBILITY; TUBERCULOSIS; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 14944377655     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2005.43319     Document Type: Article

References (20)

1. Carbone LD et al. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? Arthritis Rheum 1992; 35: 1476-82.
2. Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 2003; 3: 141-68.
3. British Society for Rheumatology, 2004. BSR guideline for prescribing TNFα blockers in adults with ankylosing spondylitis [online]. Available: http://www.msecportal.org/portal/editorial/PublicPages/bsr/536883013/ FinalAnkylosingSpondylitisGuideline.pdf [Accessed 10 February 2005].
4. McCormack PL, Wellington K. Etanercept: in ankylosing spondylitis. BioDrugs 2004; 18: 199-205.
5. Davis Jr JC et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
6. Clegg DO et al. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999; 42: 2325-9.
7. Enbrel. Summary of product characteristics, UK. Wyeth Europa Ltd, September 2004.
8. Remicade. Summary of product characteristics, The Netherlands. Centocor B.V., May 2003.
9. Garrett S et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
10. Calin A et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
11. Braun J et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
12. Braun J et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
13. Gorman JD et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349-56.
14. Brandt J et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
15. Brandt J et al, 2004. Long term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis [online]. Available: http://rheumatology.oupjournals.org/cgi/reprint/keh475v1 [Accessed 15 February 2005].
16. Calin A et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-600.
17. Zou J et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48: 780-90.
18. Braun J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
19. Van den Bosch F et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002; 46: 755-65.
20. Dawes PT et al. TNF therapy for spondyloarthropathy: can we marshal the argument? Rheumatology (Oxford) 2004; 43: 1069-71.